Investigation Launched by Pomerantz Law Firm for Sanara MedTech Investors

Pomerantz Law Firm Investigates Sanara MedTech Investors

The Pomerantz Law Firm, widely recognized for its expertise in securities litigation, has initiated an investigation concerning possible claims on behalf of investors of Sanara MedTech, Inc. (NASDAQ: SMTI). The firm aims to uncover whether Sanara and specific executives might have engaged in securities fraud or other illegal business practices.

On November 11, 2025, Sanara released news that it would cease operations for its Tissue Health Plus (THP) program, claiming a strategic move to refocus on its core surgical businesses and enhance operational efficiency. This decision, however, came with a heavy financial toll: a reported net loss from discontinued operations reaching $31.2 million, largely stemming from a non-cash asset impairment charge of $26.5 million related to the THP program closure.

As investors absorbed this troubling news, the company's stock took a significant hit, plummeting by $6.93, or 24.7%, to close at $21.11 per share on November 12, 2025. This sharp decline prompted Pomerantz LLP to launch an investigation into the circumstances surrounding these developments as they may constitute a breach of fiduciary duty to shareholders.

Founded by the late Abraham L. Pomerantz, the firm is recognized as one of the foremost in the corporate, securities, and antitrust class action arenas. With over 85 years of advocacy for victims of securities fraud and corporate misconduct, Pomerantz continues to fight for the rights of investors. The firm has a substantial history of recovering multimillion-dollar awards on behalf of class members, showcasing its commitment to holding companies accountable and ensuring investors' rights are protected.

Investors who believe they may have sustained losses due to Sanara's actions are encouraged to contact Pomerantz LLP. The firm has indicated that gathering information on these allegations will be crucial for any potential class action lawsuits that may arise as a result of this investigation.

This case highlights the significance of corporate governance and transparency as companies often shift strategies, which can directly affect shareholders' investments. It serves as a reminder to investors to remain vigilant and informed about the companies in which they invest. As new information surfaces, Pomerantz LLP will continue to update stakeholders regarding this investigation.

For more details or to participate in the class action, affected investors can reach out to Danielle Peyton at Pomerantz LLP through the provided contact number or email. Maintaining an informed investor community is essential, particularly in turbulent economic times where operational changes can yield drastic impacts on stock performance.

In conclusion, ongoing scrutiny of corporate practices is vital for sustaining trust and accountability in the financial markets. Investors are urged to stay engaged as this case develops.